Michael W Lark
Overview
Explore the profile of Michael W Lark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koblish M, Carr 3rd R, Siuda E, Rominger D, Gowen-MacDonald W, Cowan C, et al.
J Pharmacol Exp Ther
. 2017 May;
362(2):254-262.
PMID: 28533287
Prescription opioids are a mainstay in the treatment of acute moderate to severe pain. However, chronic use leads to a host of adverse consequences including tolerance and opioid-induced hyperalgesia (OIH),...
2.
Soergel D, Subach R, Burnham N, Lark M, James I, Sadler B, et al.
Pain
. 2014 Jun;
155(9):1829-1835.
PMID: 24954166
Opioids provide powerful analgesia but also efficacy-limiting adverse effects, including severe nausea, vomiting, and respiratory depression, by activating μ-opioid receptors. Preclinical models suggest that differential activation of signaling pathways downstream...
3.
Violin J, Crombie A, Soergel D, Lark M
Trends Pharmacol Sci
. 2014 Jun;
35(7):308-16.
PMID: 24878326
Drug discovery targeting G protein-coupled receptors (GPCRs) is no longer limited to seeking agonists or antagonists to stimulate or block cellular responses associated with a particular receptor. GPCRs are now...
4.
Soergel D, Subach R, Sadler B, Connell J, Marion A, Cowan C, et al.
J Clin Pharmacol
. 2013 Oct;
54(3):351-7.
PMID: 24122908
TRV130 is a G protein-biased ligand at the µ-opioid receptor. In preclinical studies it was potently analgesic while causing less respiratory depression and gastrointestinal dysfunction than morphine, suggesting unique benefits...
5.
Soergel D, Subach R, Cowan C, Violin J, Lark M
J Clin Pharmacol
. 2013 Jul;
53(9):892-9.
PMID: 23813302
TRV027 is a novel β-arrestin biased peptide ligand of the angiotensin II type 1 receptor (AT1R). The compound antagonizes G protein coupling while simultaneously stimulating β-arrestin-mediated signaling. In preclinical studies,...
6.
Violin J, Soergel D, Boerrigter G, Burnett Jr J, Lark M
Trends Cardiovasc Med
. 2013 Mar;
23(7):242-9.
PMID: 23499300
G protein-coupled receptors have been successfully targeted by numerous therapeutics including drugs that have transformed the management of cardiovascular disease. However, many GPCRs, when activated or blocked by drugs, elicit...
7.
DeWire S, Yamashita D, Rominger D, Liu G, Cowan C, Graczyk T, et al.
J Pharmacol Exp Ther
. 2013 Jan;
344(3):708-17.
PMID: 23300227
The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics. Morphine pharmacology in β-arrestin-2 knockout...
8.
Boerrigter G, Soergel D, Violin J, Lark M, Burnett Jr J
Circ Heart Fail
. 2012 Aug;
5(5):627-34.
PMID: 22891045
Background: TRV120027 is a novel β-arrestin biased ligand of the angiotensin II type 1 receptor; it antagonizes canonical G-protein-mediated coupling while, in contrast to classical angiotensin II type 1 receptor...
9.
Boerrigter G, Lark M, Whalen E, Soergel D, Violin J, Burnett Jr J
Circ Heart Fail
. 2011 Aug;
4(6):770-8.
PMID: 21835984
Background: The angiotensin II type 1 receptor (AT1R) plays a key role in regulating cardiorenal function. Classic "unbiased" AT1R antagonists block receptor coupling to both G(αq) and ß-arrestin-mediated signals, which...
10.
Violin J, DeWire S, Yamashita D, Rominger D, Nguyen L, Schiller K, et al.
J Pharmacol Exp Ther
. 2010 Aug;
335(3):572-9.
PMID: 20801892
Biased G protein-coupled receptor ligands engage subsets of the receptor signals normally stimulated by unbiased agonists. However, it is unclear whether ligand bias can elicit differentiated pharmacology in vivo. Here,...